CRISPR Could Cause Cancer? Here Are 3 Reasons Investors Shouldn't Panic [The Motley Fool]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: The Motley Fool
Newly identified potential issues with CRISPR-Cas9 gene editing aren't as worrisome as you might think. First do no harm. That's a core principle for treating patients. But a promising gene-editing method called CRISPR-Cas9 could potentially harm patients. Two papers published in Nature Medicine on Monday raised concerns that using CRISPR-Cas9 to edit genes could increase the chances that cancer cells develop. The stocks of CRISPR Therapeutics ( NASDAQ:CRSP ) , Editas Medicine ( NASDAQ:EDIT ) , and Intellia Therapeutics ( NASDAQ:NTLA ) plunged on the news . All three of these biotechs are pioneering development of gene-editing therapies using CRISPR-Cas9. But should investors panic because of the possibility that CRISPR-Cas9 could cause cancer? Not at all. Here are three reasons why you should remain calm. Image source: Getty Images. 1. It's still early Do initial research findings in the scientific community sometimes prove to be inco
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- Is Vertex Pharmaceuticals Stock a Millionaire Maker? [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics AG (NASDAQ: CRSP) had its price target raised by analysts at Citigroup Inc. from $88.00 to $89.00. They now have a "buy" rating on the stock.MarketBeat
- Bullish Trendline Has Never Failed Crispr Therapeutics Stock [Yahoo! Finance]Yahoo! Finance
- Is Trending Stock CRISPR Therapeutics AG (CRSP) a Buy Now? [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know [Yahoo! Finance]Yahoo! Finance
CRSP
Earnings
- 2/21/24 - Beat
CRSP
Sec Filings
- 4/17/24 - Form 4
- 4/15/24 - Form 144
- 4/10/24 - Form SC
- CRSP's page on the SEC website